计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A136009-250mg |
250mg |
现货 ![]() |
| |
| A136009-1g |
1g |
现货 ![]() |
| |
| A136009-5g |
5g |
现货 ![]() |
|
| 别名 | 2-氨基-7-异丙基-5-氧代色满[2,3-b]吡啶-3-甲酸 |
|---|---|
| 英文别名 | AMLEXANOX (MART.) | CHX 3673 | OraDisc A | ANW | aphtheal | US10214536, Amlexanox | Amlexanox- Bio-X | 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid | 2-Amino-7-isopropyl-5-oxo-5H-[1]benzopyrano[2,3-b] pyridine-3-carboxylic |
| 规格或纯度 | Moligand™, ≥98%(HPLC) |
| 英文名称 | Amlexanox |
| 生化机理 | 选择性TBK1和IKKε抑制剂(IC 50 = 1-2μM)。在体内显示出抗过敏,抗肥胖和抗炎作用。口服具有活性 |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 磷酸二酯酶 4 抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 纯度 | ≥98%(HPLC) |
| ALogP | 3.1 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504750534 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid |
| INCHI | 1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21) |
| InChi Key | SGRYPYWGNKJSDL-UHFFFAOYSA-N |
| Smiles | CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N |
| Isomeric SMILES | CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N |
| 分子量 | 298.29 |
| Reaxy-Rn | 556384 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=556384&ln= |
| 敏感性 | 对空气敏感 |
|---|---|
| 熔点 | 300 °C |
| 分子量 | 298.290 g/mol |
| XLogP3 | 3.100 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 2 |
| 精确质量Exact Mass | 298.095 Da |
| 单同位素质量Monoisotopic Mass | 298.095 Da |
| 拓扑极表面积Topological Polar Surface Area | 103.000 Ų |
| 重原子数Heavy Atom Count | 22 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 467.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P330: 漱口 P301+P312: 如误吞咽:如感觉不适,呼叫急救中心/医生。 P501: 将内容物/容器处理到。。。 |
| WGK Germany | 3 |
| Merck Index | 490 |
¥164.72
| 1. Bell J. (2005) Amlexanox for the treatment of recurrent aphthous ulcers.. Clin Drug Investig, 25 (9): (555-66). [PMID:17532700] |
| 2. Spina D. (2008) PDE4 inhibitors: current status.. Br J Pharmacol, 155 (3): (308-15). [PMID:18660825] |
| 3. Elad S, Epstein JB, von Bültzingslöwen I, Drucker S, Tzach R, Yarom N. (2011) Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents.. Expert Opin Emerg Drugs, 16 (1): (183-202). [PMID:21244328] |
| 4. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White NM, Hochberg I et al.. (2013) An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.. Nat Med, 19 (3): (313-21). [PMID:23396211] |
| 5. Makino H, Saijo T, Ashida Y, Kuriki H, Maki Y. (1987) Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase.. Int Arch Allergy Appl Immunol, 82 (1): (66-71). [PMID:2433225] |
| 6. Mowers J, Uhm M, Reilly SM, Simon J, Leto D, Chiang SH, Chang L, Saltiel AR. (2013) Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.. Elife, 2 (e01119). [PMID:24368730] [10.7554/eLife.01119] |
| 7. Hansen IS, Krabbendam L, Bernink JH, Loayza-Puch F, Hoepel W, van Burgsteden JA, Kuijper EC, Buskens CJ, Bemelman WA, Zaat SAJ et al.. (2018) FcαRI co-stimulation converts human intestinal CD103+dendritic cells into pro-inflammatory cells through glycolytic reprogramming.. Nat Commun, 9 (1): (863). [PMID:29491406] |
| 8. Adzika GK et al.. (2021) Amlexanox and Forskolin Prevents Isoproterenol-Induced Cardiomyopathy by Subduing Cardiomyocyte Hypertrophy and Maladaptive Inflammatory Responses.. Front Cell Dev Biol, 9 (719351). [PMID:34631707] |
| 9. McCarthy GM et al.. (2018) Chronic ethanol consumption: role of TLR3/TRIF-dependent signaling.. Addict Biol, 23 (3): (889-903). [PMID:28840972] |
| 10. Adzika GK et al.. (2021) Isoproterenol-Induced Cardiomyopathy Recovery Intervention: Amlexanox and Forskolin Enhances the Resolution of Catecholamine Stress-Induced Maladaptive Myocardial Remodeling.. Front Cardiovasc Med, 8 (719805). [PMID:34901202] |
| 11. Huh JY et al.. (2020) TANK-Binding Kinase 1 Regulates the Localization of Acyl-CoA Synthetase ACSL1 to Control Hepatic Fatty Acid Oxidation.. Cell Metab, 32 (6): (1012-1027.e7). [PMID:33152322] |
| 12. Sawaged S et al.. (2022) TBK1 and GABARAP family members suppress Coxsackievirus B infection by limiting viral production and promoting autophagic degradation of viral extracellular vesicles.. PLoS Pathog, 18 (8): (e1010350). [PMID:36044516] |
| 13. Zhao P et al.. (2018) TBK1 at the Crossroads of Inflammation and Energy Homeostasis in Adipose Tissue.. Cell, 172 (4): (731-743.e12). [PMID:29425491] |
| 14. Zhao P et al.. (2022) The TBK1/IKKe inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis.. JCI Insight, 7 (17): [PMID:35917178] |
| 15. Eintracht J et al.. (2021) Translational readthrough of ciliopathy genes BBS2 and ALMS1 restores protein, ciliogenesis and function in patient fibroblasts.. EBioMedicine, 70 (103515). [PMID:34365092] |